| Schizophrenia
Invega Sustenna vs Uzedy
Side-by-side clinical, coverage, and cost comparison for schizophrenia.Deep comparison between: Invega Sustenna vs Uzedy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUzedy has a higher rate of injection site reactions vs Invega Sustenna based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Uzedy but not Invega Sustenna, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Invega Sustenna
Uzedy
At A Glance
IM injection
Every 4 weeks
D2/5HT2A antagonist
SC injection
Every 4-8 weeks
Atypical antipsychotic
Indications
- Schizophrenia
- Schizoaffective Disorder
- Schizophrenia
- Bipolar I disorder
Dosing
Schizophrenia Initiation: 234 mg deltoid on Day 1, 156 mg deltoid on Day 8; recommended monthly maintenance 117 mg (range 39-234 mg) in deltoid or gluteal muscle; maximum monthly dose 234 mg.
Schizoaffective Disorder Initiation: 234 mg deltoid on Day 1, 156 mg deltoid on Day 8; monthly maintenance 78-234 mg adjusted for tolerability and/or efficacy in deltoid or gluteal muscle; maximum monthly dose 234 mg.
Mild renal impairment (creatinine clearance >=50 mL/min) Initiation: 156 mg deltoid on Day 1, 117 mg deltoid on Day 8; monthly maintenance 39-156 mg; maximum monthly dose 156 mg.
Schizophrenia Once monthly SC injection (50 mg, 75 mg, 100 mg, or 125 mg) or once every 2 months (100 mg, 150 mg, 200 mg, or 250 mg) based on equivalent daily oral risperidone dose (2-5 mg); initiate the day after last oral dose, no loading dose required.
Bipolar I disorder Once monthly SC injection (50 mg, 75 mg, or 100 mg) as monotherapy or adjunctive therapy to lithium or valproate, based on equivalent daily oral risperidone dose (2-4 mg); once every 2 months dosing is not recommended for this indication.
Contraindications
- Known hypersensitivity to paliperidone, risperidone, or any excipient in the INVEGA SUSTENNA formulation
- Known hypersensitivity to risperidone, its metabolite paliperidone, or any of its components
Adverse Reactions
Most common (>=5%) Injection site reactions, somnolence/sedation, dizziness, akathisia, extrapyramidal disorder
Serious Increased mortality in elderly patients with dementia-related psychosis, cerebrovascular adverse reactions, neuroleptic malignant syndrome, QT prolongation, tardive dyskinesia, metabolic changes, orthostatic hypotension and syncope, leukopenia/neutropenia/agranulocytosis, hyperprolactinemia, seizures
Postmarketing Angioedema, anaphylactic reaction, catatonia, ileus, somnambulism, swollen tongue, thrombotic thrombocytopenic purpura, urinary incontinence, urinary retention
Most common (>5%) Parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety, blurred vision, nausea, vomiting, upper abdominal pain, stomach discomfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, weight gain, fatigue, rash, nasal congestion, upper respiratory tract infection, nasopharyngitis, pharyngolaryngeal pain
Serious Increased mortality in elderly patients with dementia-related psychosis, cerebrovascular adverse events, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, hyperprolactinemia, orthostatic hypotension and syncope, leukopenia, neutropenia, agranulocytosis, seizures, dysphagia, priapism
Postmarketing Alopecia, anaphylactic reaction, angioedema, atrial fibrillation, cardiopulmonary arrest, diabetic ketoacidosis, Stevens-Johnson syndrome and toxic epidermal necrolysis, sudden death, thrombocytopenia, injection site pain
Pharmacology
Paliperidone palmitate is hydrolyzed to paliperidone, the major active metabolite of risperidone; its therapeutic effect in schizophrenia may be mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism, with additional antagonist activity at histamine H1 and alpha-1/alpha-2 adrenergic receptors.
Risperidone is an atypical antipsychotic whose therapeutic activity may be mediated through combined dopamine Type 2 (D2) and serotonin Type 2 (5HT2) receptor antagonism; clinical effect results from the combined concentrations of risperidone and its major active metabolite, 9-hydroxyrisperidone (paliperidone).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Invega Sustenna
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (4/12) · Qty limit (11/12)
Uzedy
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Invega Sustenna
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Uzedy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Invega Sustenna
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Uzedy
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Cancer-Related Behavioral Health
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableHealthWell: Movement Disorders - Medicare Access
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Invega SustennaView full Invega Sustenna profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.